Publications
Publications 10226 - 10250 de 33557
| Titre | DOI |
|---|---|
|
Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2 G.S. Sonke; L.L. Hart; M. Campone; F. Erdkamp; W. Janni; S. Verma; C. Villanueva; E. Jakobsen; E. Alba; E. Wist; A.M. Favret; T. Bachelot; R. Hegg; P. Wheatley-Price; F. Souami; S. Sutradhar; M. Miller; C. Germa; H.A. Burris 2017 |
10.1016/S0959-8049(17)30091-6 |
|
Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2 G.S. Sonke; L.L. Hart; M. Campone; F. Erdkamp; W. Janni; S. Verma; C. Villanueva; E. Jakobsen; E. Alba; E. Wist; A.M. Favret; T. Bachelot; R. Hegg; P. Wheatley-Price; F. Souami; S. Sutradhar; M. Miller; C. Germa; H.A. Burris 2017 |
|
|
Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy L. Berchtold; G. Zanetta; K. Dahan; F. Mihout; J. Peltier; D. Guerrot; I. Brocheriou; P. Ronco; H. Debiec 2018 |
10.1016/j.ekir.2017.09.009 |
|
Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study M. Ferreira; R. Borie; B. Crestani; P. Rigaud; L. Wemeau; D. Israel-Biet; S. Leroy; S. Quetant; L. Plantier; J.C. Dalphin; V. Cottin; S. Marchand-Adam; O.L. Network 2020 |
10.1016/j.rmed.2020.106146 |
|
EFFICACY AND SAFETY OF RVWF PROPHYLAXIS IN SEVERE VON WILLEBRAND DISEASE: PROSPECTIVE, OPEN, INTERNATIONAL, MULTICENTRE PHASE III STUDY F.W.G. Leebeek; K. Kavakli; F. Genre-Volot; F. Peyvandi; W. Miesbach; A. Shapiro; M. Timofeeva; I. Vidal; L. Martell; S. Abrol; G. Ozen; B. Mellgard 2019 |
|
|
Efficacy and safety of semaglutide 1.0 mg once weekly vs liraglutide 1.2 mg once daily as add-on to 1-3 oral glucose-lowering drugs in subjects with type 2 diabetes (SUSTAIN 10) M.S. Capehorn; A.M. Catarig; J.K. Furberg; A. Janez; H.C. Price; S. Tadayon; B. Verges; M. Marre 2019 |
|
|
Efficacy and safety of semaglutide 1.0mg once weekly vs liraglutide 1.2mg once daily as add-on to 1-3 oral antidiabetic drugs in subjects with Type 2 diabetes (SUSTAIN 10) M. Capehorn; A. Janez; H. Price; B. Verges; A.M. Catarig; K. Furberg; S. Tadayon; M. Marre 2019 |
|
|
Efficacy and safety of semaglutide 1.0mg once weekly vs liraglutide 1.2mg once daily as add-on to 1-3 oral antidiabetic drugs in subjects with Type 2 diabetes (SUSTAIN 10) M. Capehorn; A. Janez; H. Price; B. Verges; A.M. Catarig; K. Furberg; S. Tadayon; M. Marre 2019 |
|
|
Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated by bevacizumab with or without interferon therapy: Results from pooled analysis of AVATOR, CHANGE, and TRAIN studies. A. Thiery-Vuillemin; A. Guillot; T. Steiner; E. Herrmann; K.N. Syrigos; N. Kelkouli; A. Cattaneo; T. Nguyen 2016 |
10.1200/jco.2016.34.2_suppl.585 |
|
Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study A. Thiery-Vuillemin; C. Theodore; L. Jacobasch; J. Schmitz; C. Papandreou; A. Guillot; C. Emmanouilides; K. Slimane; N. Kelkouli; S. Kim; T.Nguyen Tan Hon 2015 |
10.1016/j.clgc.2014.09.005 |
|
Efficacy and Safety of SIB Delivered with Helical Tomotherapy and Daily IGRT for Rectal Cancer E. Chammah; A. Duhram; B. Pichon; M. Montemurro; D. Hanhloser; B. De Bari 2018 |
10.1016/S0167-8140(18)31807-3 |
|
Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study C. Jackisch; D. Stroyakovskiy; X. Pivot; J.S. Ahn; B. Melichar; S.C. Chen; C. Meyenberg; N. Al-Sakaff; D. Heinzmann; R. Hegg 2018 |
|
|
Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study C. Jackisch; D. Stroyakovskiy; X. Pivot; J.S. Ahn; B. Melichar; S.C. Chen; C. Meyenberg; N. Al-Sakaff; D. Heinzmann; R. Hegg 2018 |
|
|
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study X. Pivot; S. Verma; L. Fallowfield; V. Mueller; M. Lichinitser; V. Jenkins; S. Munoz; Z. Machackova; S. Osborne; J. Gligorov; P.H.Study Grp 2017 |
10.1016/j.ejca.2017.08.019 |
|
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study X. Pivot; S. Verma; L. Fallowfield; V. Mueller; M. Lichinitser; S. Munoz; Z. Machackova; S. Osborne; J. Gligorov 2016 |
10.1093/annonc/mdw364.65 |
|
Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial E. Bosi; P. Choudhary; H.W. de Valk; S. Lablanche; J. Castaneda; S. de Portu; J. Da Silva; R. Re; L.Vorrink de Groot; J. Shin; F.R. Kaufman; O. Cohen; E. Bosi; A. Laurenzi; A. Caretto; P. Choudhary; D. Slatterly; M. Henderson-Wilson; J. Weisnagel; M.C. Dube; V.E. Julien; R. Trevisan; G. Lepore; R. Bellante; I. Hramiak; T. Spaic; M. Driscoll; S. Borot; A. Clergeot; L. Khiat; P. Hammond; S. Ray; L. Dinning; G. Tonolo; A. Manconi; M.Serena Ledda; H. de Valk; W. de Ranitz; B. Silvius; A. Wojtusciszyn; A. Farret; T. Vriesendorp; F.Immeker de Jong; J. van der Linden; H.S. Brink; M. Alkemade; P. Schaepelynck-Belicar; S. Galie; C. Treglia; S. Lablanche; P.Y. Benhamou; M. Haddouche; R. Hoogma; L. Leelarathna; A. Shaju; L. James; S.M.I.L.E.Study Grp 2019 |
10.1016/S2213-8587(19)30150-0 |
|
EFFICACY AND SAFETY OF TNF ANTAGONISTS IN OCULAR SARCOIDOSIS: DATA FROM THE FRENCH REGISTRY STAT A. Marquet; C. Chapelon-Abric; D. Maucort-Boulch; F. Cohen-Aubart; L. Perard; L. Bouillet; S. Abad; P. Bielefeld; D. Bouvry; M. Andre; N. Noel; B. Bienvenu; A. Proux; S. Vukusic; B. Bodaghi; F. Sarrot-Reynaud; J. Iwaz; C. Broussolle; D. Saadoun; Y. Jamilloux; D. Valeyre; P. Seve; G.Sarcoidose Francophone 2017 |
|
|
EFFICACY AND SAFETY OF TNF ANTAGONISTS IN OCULAR SARCOIDOSIS: DATA FROM THE FRENCH REGISTRY STAT A. Marquet; C. Chapelon-Abric; D. Maucort-Boulch; F. Cohen-Aubart; L. Perard; L. Bouillet; S. Abad; P. Bielefeld; D. Bouvry; M. Andre; N. Noel; B. Bienvenu; A. Proux; S. Vukusic; B. Bodaghi; F. Sarrot-Reynaud; J. Iwaz; C. Broussolle; D. Saadoun; Y. Jamilloux; D. Valeyre; P. Seve; G.Sarcoidose Francophone 2017 |
|
|
Efficacy and safety of TNF-alpha inhibitors in non-infectious uveitis : a multicenter retrospective study M. Bidaut-Garnier; H. Vallet; P. Seve; E. Heron; A. Perlat; N. Tieulie; L. Perard; P. Lehoang; D. Saadoun; B. Bodaghi 2014 |
|
|
Efficacy and safety of TNF-alpha inhibitors in non-infectious uveitis : a multicenter retrospective study M. Bidaut-Garnier; H. Vallet; P. Seve; E. Heron; A. Perlat; N. Tieulie; L. Perard; P. Lehoang; D. Saadoun; B. Bodaghi 2014 |
|
|
Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis Y.M. Pers; R. Schaub; E. Constant; J. Lambert; M. Godfrin-Valnet; C. Fortunet; W. Bourichi; B.Pallot Prades; D. Wendling; P. Gaudin; C. Jorgensen; J.F. Maillefert; H. Marotte 2015 |
10.1016/j.jbspin.2014.107.010 |
|
EFFICACY AND SAFETY OF TOCILIZUMAB IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS Y.M. Pers; R. Schaub; C. Fortunet; E. Constant; J. Lambert; M. Godfrin-Valnet; B. Pallot-Prades; D. Wendling; P. Gaudin; H. Marotte; J.F. Maillefert; C. Jorgensen 2014 |
10.1136/annrheumdis-2014-eular.1513 |
|
Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients Y. Jamilloux; F. Cohen-Aubart; C. Chapelon-Abric; D. Maucort-Boulch; A. Marquet; L. Perard; L. Bouillet; A. Deroux; S. Abad; P. Bielefeld; D. Bouvry; M. Andre; N. Noel; B. Bienvenu; A. Proux; S. Vukusic; B. Bodaghi; F. Sarrot-Reynauld; J. Iwaz; Z. Amoura; C. Broussolle; P. Cacoub; D. Saadoun; D. Valeyre; P. Seve; G.Sarcoidose Francophone 2017 |
10.1016/j.semarthrit.2017.03.005 |
|
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study C. Borg; G. Mantion; F. Boudghene; F. Mornex; F. Ghiringhelli; A. Adenis; D. Azria; J. Balosso; M. Ben Abdelghani; J.Baptiste Bachet; V. Vendrely; Y. Francois; T. Conroy; E. Rio; B. Roullet; D. Spaeth; L. Quero; Z. Lakkis; M. Coudert; M. Ionescu-Goga; A. Tanang; T. Andre 2019 |
10.1016/j.clcc.2019.04.006 |
|
Efficacy and safety of Wilfactin administered by continuous intravenous infusion in severe von Willebrand disease patients undergoing major surgery J. Windyga; B. Guillet; L. Rugieri; M.A. Bertrand; E. Stefanska; C. Negrier; A.C. Jaffry; N. Knuchel; C. Henriet; F. Bridey 2014 |